晚期黑色素瘤免疫疗法及其联合疗法的最新进展：综述
Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review.
作者信息
Xu Jiamin, Mu Shukun, Wang Yun, Yu Suchun, Wang Zhongming
机构信息
School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Department of Radiation Oncology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
出版信息
Front Oncol. 2024 Jul 16;14:1400193. doi: 10.3389/fonc.2024.1400193. eCollection 2024.
Abstract
The incidence of melanoma is increasing year by year and is highly malignant, with a poor prognosis. Its treatment has always attracted much attention. Among the more clinically applied immunotherapies are immune checkpoint inhibitors, bispecific antibodies, cancer vaccines, adoptive cell transfer therapy, and oncolytic virotherapy. With the continuous development of technology and trials, in addition to immune monotherapy, combinations of immunotherapy and radiotherapy have shown surprising efficacy. In this article, we review the research progress of immune monotherapy and combination therapy for advanced melanoma, with the aim of providing new ideas for the treatment strategy for advanced melanoma.
摘要
黑色素瘤的发病率逐年上升，且恶性程度高，预后较差。其治疗一直备受关注。在临床上应用较多的免疫疗法包括免疫检查点抑制剂、双特异性抗体、癌症疫苗、过继性细胞转移疗法和溶瘤病毒疗法。随着技术的不断发展和试验的进行，除了免疫单药治疗外，免疫疗法与放射疗法的联合已显示出惊人的疗效。在本文中，我们综述了晚期黑色素瘤免疫单药治疗和联合治疗的研究进展，旨在为晚期黑色素瘤的治疗策略提供新思路。
相似文献
1
Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review.晚期黑色素瘤免疫疗法及其联合疗法的最新进展：综述
Front Oncol. 2024 Jul 16;14:1400193. doi: 10.3389/fonc.2024.1400193. eCollection 2024.
2
Intratumoral Immunotherapy-Update 2019.肿瘤内免疫治疗-2019 更新。
Oncologist. 2020 Mar;25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438. Epub 2019 Nov 29.
3
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.超越免疫检查点抑制剂：黑色素瘤治疗中的新兴靶点。
Curr Oncol Rep. 2024 Jul;26(7):826-839. doi: 10.1007/s11912-024-01551-4. Epub 2024 May 25.
4
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials.晚期黑色素瘤的治疗：1 期和 2 期临床试验中联合免疫检查点抑制剂的系统和局部治疗的综述。
Expert Opin Investig Drugs. 2022 Jan;31(1):95-104. doi: 10.1080/13543784.2022.2027366. Epub 2022 Jan 17.
5
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.溶瘤单纯疱疹病毒联合免疫检查点阻断克服了 T 细胞受体信号功能障碍的晚期黑色素瘤免疫冷模型中的治疗抵抗。
J Immunother Cancer. 2024 Jul 25;12(7):e009443. doi: 10.1136/jitc-2024-009443.
6
From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review.从传统疗法到免疫疗法：黑色素瘤治疗综述
Cancers (Basel). 2020 Oct 20;12(10):3057. doi: 10.3390/cancers12103057.
7
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告。那不勒斯，2015年12月1日至4日
J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y.
8
Immunotherapy in melanoma: Recent advances and future directions.黑色素瘤的免疫疗法：最新进展与未来方向。
Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2.
9
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.免疫治疗胰腺癌的前沿和未来：从分子机制到临床应用。
Front Immunol. 2024 May 2;15:1383978. doi: 10.3389/fimmu.2024.1383978. eCollection 2024.
10
The Role of Oncolytic Viruses in the Treatment of Melanoma.溶瘤病毒在黑色素瘤治疗中的作用。
Curr Oncol Rep. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3.
引用本文的文献
1
Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications.雄激素受体在黑色素瘤中的作用：肿瘤进展、免疫逃逸机制及治疗意义
Cancers (Basel). 2025 Aug 29;17(17):2828. doi: 10.3390/cancers17172828.
2
Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies.应对黑色素瘤放射抗性：机制与治疗策略
Cancers (Basel). 2025 Aug 14;17(16):2648. doi: 10.3390/cancers17162648.
3
Cancer Immunotherapy-An Overview.癌症免疫疗法——概述
Cancer Treat Res. 2025;129:1-16. doi: 10.1007/978-3-031-97242-3_1.
4
Advances in Melanoma and Skin Cancers.黑色素瘤与皮肤癌的进展
Int J Mol Sci. 2025 Feb 21;26(5):1849. doi: 10.3390/ijms26051849.
5
Advancements and Challenges in Personalized Therapy for -Mutant Melanoma: A Comprehensive Review.- 突变型黑色素瘤个性化治疗的进展与挑战：综述
J Clin Med. 2024 Sep 12;13(18):5409. doi: 10.3390/jcm13185409.
本文引用的文献
1
Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line.肿瘤浸润淋巴细胞癌症疗法接近美国食品药品监督管理局审批终点
Nat Rev Drug Discov. 2024 Jan;23(1):3-7. doi: 10.1038/d41573-023-00206-6.
2
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.KN046 是一种新型的 PD-L1 和 CTLA-4 双特异性抗体，在晚期实体瘤患者中的 I 期临床试验。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006654.
3
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.纳武利尤单抗联合瑞派利单抗对比纳武利尤单抗单药治疗既往未治疗的不可切除或转移性黑色素瘤患者的健康相关生活质量：RELATIVITY-047试验
Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22.
4
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.QL1706（PSB205）是一种 PD1/CTLA4 双功能阻断剂，在晚期实体瘤患者中的首次人体 I/ Ib 期研究。
J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1.
5
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.替莫唑胺联合依匹单抗对比依匹单抗单药治疗晚期黑色素瘤：一项多中心、随机、开放标签、二期临床试验的 5 年最终分析。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006270.
6
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.在荷兰全国范围内的晚期黑色素瘤患者队列中，Ipilimumab 联合 Nivolumab 联合治疗的真实世界结局。
J Immunother. 2023 Jun 1;46(5):197-204. doi: 10.1097/CJI.0000000000000468. Epub 2023 Apr 28.
7
mRNA Vaccine Slows Melanoma Recurrence.mRNA 疫苗减缓黑色素瘤复发。
Cancer Discov. 2023 Jun 2;13(6):1278. doi: 10.1158/2159-8290.CD-NB2023-0028.
8
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.使用免疫检查点抑制剂（ICI）的癌症免疫疗法：潜力、耐药机制以及在获得耐药性时恢复T细胞反应性的策略。
Cancer Cell Int. 2023 Apr 10;23(1):64. doi: 10.1186/s12935-023-02902-0.
9
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).免疫检查点抑制剂和 Carbon iON 放疗在稳定疾病的实体瘤中的应用（ICONIC）。
Future Oncol. 2023 Jan;19(3):193-203. doi: 10.2217/fon-2022-0503. Epub 2023 Mar 28.
10
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.卡度尼利单抗，一种四价 PD-1/CTLA-4 双特异性抗体，具有 Trans-Binding 及增强的靶标结合亲和力。
MAbs. 2023 Jan-Dec;15(1):2180794. doi: 10.1080/19420862.2023.2180794.
Zotero 插件